The earnings call presented a mixed picture with significant revenue growth and strategic acquisitions, but also highlighted challenges like increased operating expenses and a decline in the US prescription channel revenue. The positive aspects of revenue growth and new opportunities were tempered by operational and financial challenges.

Company Guidance -

Q2 2025

During the electroCore First Quarter 2025 Earnings Conference Call, CEO Dan Goldberger provided guidance indicating a promising outlook for the company's growth trajectory. The company reported a 23% year-over-year revenue increase to $6.7 million, driven by a strong performance in the VA channel and the successful expansion of the Truvaga brand, which saw a 187% increase in net sales. Gross margins remained robust at 85%, and the company anticipates maintaining these levels. Goldberger highlighted the strategic acquisition of the Quell product line and the distribution agreement with Spark Biomedical, both of which are expected to diversify revenue streams and enhance market presence. The company is investing in sales and marketing efforts to support these initiatives, with a focus on scaling the Truvaga brand and integrating new products into existing channels. Additionally, the company is targeting a path to profitability with a goal of achieving $9 million in quarterly revenue, a 34% increase from the current quarter. The overall guidance reflects a confident outlook, emphasizing growth in core business lines and the integration of new products to capitalize on emerging opportunities in the bioelectronic technology sector.

Revenue Growth

electroCore reported revenue of $6.7 million in Q1 2025, a 23% increase over Q1 2024.

Gross Margin Increase

Gross margins improved to 85% in Q1 2025, compared to 84% in Q1 2024.

Truvaga Brand Expansion

Truvaga net sales were approximately $1.1 million in Q1 2025, a 187% increase from Q1 2024.

Acquisition of NeuroMetrix's Quell Platform

The acquisition aims to accelerate electroCore's mission in the bioelectronic health and wellness sector.

New Distribution Agreement with Spark Biomedical

Agreement to distribute the Sparrow Ascent product line for the treatment of opioid withdrawal symptoms.

Electrocore (ECOR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ECOR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 06, 2025	2025 (Q2)	-0.33 / -	-0.38	―	―	―
May 07, 2025	2025 (Q1)	-0.48 / -0.47	-0.53	11.32% (+0.06)	―
Mar 12, 2025	2024 (Q4)	-0.30 / -0.37	-0.61	39.34% (+0.24)	―
Nov 13, 2024	2024 (Q3)	-0.33 / -0.31	-0.68	54.41% (+0.37)	―
Aug 07, 2024	2024 (Q2)	-0.43 / -0.38	-1.03	63.11% (+0.65)	―
May 08, 2024	2024 (Q1)	-0.59 / -0.53	-1.24	57.26% (+0.71)	―
Mar 13, 2024	2023 (Q4)	-0.59 / -0.61	-1.22	50.00% (+0.61)	―
Nov 08, 2023	2023 (Q3)	-0.70 / -0.68	-1.2	43.33% (+0.52)	―
Aug 09, 2023	2023 (Q2)	-0.96 / -1.03	-1.2	14.17% (+0.17)	―
May 03, 2023	2023 (Q1)	-1.00 / -1.24	-1.2	-3.33% (-0.04)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ECOR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2025	$6.81	$5.19	-23.79%
Mar 12, 2025	$13.00	$9.55	-26.54%
Nov 13, 2024	$13.40	$13.60	+1.49%
Aug 07, 2024	$6.10	$6.02	-1.31%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Electrocore (ECOR) report earnings?

Electrocore (ECOR) is schdueled to report earning on Aug 06, 2025, TBA (Confirmed).

What is Electrocore (ECOR) earnings time?

Electrocore (ECOR) earnings time is at Aug 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ECOR EPS forecast?

ECOR EPS forecast for the fiscal quarter 2025 (Q2) is -0.33.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing